MAPT and Alzheimer disease: To rule out AD, multiple biomarkers are available, like cerebrospinal fluid (CSF) molecules (for example, amyloid and tau), and to see atrophy in the brain, various neuroimaging techniques, such as computed tomography, magnetic resonance imaging, or positron emission tomography (PET).